Nephros (NASDAQ:NEPH) Trading 16.4% Higher – What’s Next?

Nephros, Inc. (NASDAQ:NEPHGet Free Report)’s share price rose 16.4% on Thursday . The company traded as high as $2.67 and last traded at $2.63. Approximately 71,249 shares were traded during trading, an increase of 486% from the average daily volume of 12,163 shares. The stock had previously closed at $2.26.

Nephros Stock Up 16.4%

The stock has a market capitalization of $27.88 million, a P/E ratio of -29.22 and a beta of 0.81. The company has a fifty day moving average price of $1.91 and a 200-day moving average price of $1.68.

Nephros (NASDAQ:NEPHGet Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported $0.05 earnings per share (EPS) for the quarter. Nephros had a negative return on equity of 11.39% and a negative net margin of 6.86%. The business had revenue of $4.88 million for the quarter, compared to analysts’ expectations of $3.67 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nephros stock. Topline Capital Management LLC bought a new position in Nephros, Inc. (NASDAQ:NEPHFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 419,887 shares of the company’s stock, valued at approximately $617,000. Topline Capital Management LLC owned 3.98% of Nephros as of its most recent filing with the SEC. Hedge funds and other institutional investors own 41.10% of the company’s stock.

About Nephros

(Get Free Report)

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Featured Articles

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.